NEW YORK, March 25 - Agencourt Bioscience on Monday said that the Duke University Medical Center has picked its Solid Phase Reversible Immobilization technology to help its cancer research.

The deal, funded by the National Cancer Institute's Cancer Genome Anatomy Project, will give researchers at Duke's Brain Cancer Genomics Laboratory access to Agencourt's SPRI technology to help them determine the molecular anatomy of normal, pre-cancer, and cancer cells. Terms also call for Agencourt to sequence Duke's SAGE libraries.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.